-
2022-501417-31-00
5
High-risk Resected Melanoma
-
2024-518275-64-00
4
Diffuse large B-cell lymphomas (DLBCL, Diffuse large B-cell lymphoma)
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-521587-35-00
5
Metastatic colorectal cancer
-
2025-523005-15-00
9
Non-Hodgkin Lymphoma
-
2025-523017-28-00
5
Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Nec
-
2025-523058-16-00
4
Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhib
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma
-
2026-525263-41-00
5
Hodgkin lymphoma
-
2025-522888-15-00
3
2026-05-27
Small Cell Lung Cancer
-
2025-524001-33-00
4
2026-05-22
Graves’ Disease
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-516616-24-00
5
2025-07-23
Acromegaly
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2023-505606-42-00
5
2024-10-15
Head and Neck Squamous Cell Carcinoma (HNSCC)
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2022-503055-26-00
9
2023-10-30
Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2024-516993-31-00
5
2026-05-11
Renal Cell Carcinoma
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-521043-20-00
10
2026-01-27
Neuroendocrine tumors
-
2025-521828-30-00
9
2026-01-27
Advanced Solid Tumors